INTRODUCTION
The market for generic cancer products is set to undergo a period of rapid
expansion over the next decade as an increasing number of high revenue cancer
products lose patent protection. Additionally, the increasing emphasis on
cost-containment within the major markets should further encourage the growth of
the generics market. Generics manufacturers and innovative pharmaceuticals need
to assess their strategic options to exploit the developing market, or defend
their product sales respectively.
SCOPE OF THIS REPORT
Analysis of the current maturity of the cancer generics market in the seven
major markets, and factors influencing market growth
Strategies for both generics manufacturers and research-based pharmaceuticals to
maximize product sales as the generics market develops
Analysis of key companies specializing in the cancer generics market
REPORT HIGHLIGHTS
Over $15bn worth of cancer drugs are predicted to lose patent-protection by
2010, generating substantial opportunity for generics manufacturers within the
oncology market. Datamonitor believes that generics manufacturers must now focus
on distinguishing their portfolio from competitors, whilst innovative
pharmaceutical companies must ensure an expansive innovative pipeline and
maximize the patent-protected lifecycle of their products to defend their
revenue stream from generics.
KEY REASONS TO BUY THIS REPORT
Understand the impact that the loss of patent protection will have on sales
of innovative products, and how to limit revenue loss
Evaluate how the changing regulatory and cost-containment environments within
the seven major markets will affect the growth of the generics industry
Assess how to competitively position your company within either the innovative
pharmaceuticals or generics market to gain a strategic advantage
View Cart
